Edesa Biotech, Inc. (EDSA) 10-Year Financial Performance & Capital Metrics

EDSA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutEdesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.Show more

Revenue $0
EBITDA -$7M +24.5%
Net Income -$6M +26.3%
EPS (Diluted) -1.93 +34.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -136.66% -34.1%
ROIC -383.24% -13.6%
Debt/Equity 0.01 -25.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 11.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM39.82%

ROCE

10Y Avg-96.1%

5Y Avg-145.97%

3Y Avg-143.22%

Latest-155.03%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	758.69K	1.27M	228.29K	211.85K	410.87K	328.8K	0	0	0	0
Revenue Growth %	1.04%	0.68%	-0.82%	-0.07%	0.94%	-0.2%	-1%	-	-	-
Cost of Goods Sold+	840.25K	1.13M	534.45K	445.32K	101.29K	17.6K	118.79K	118.19K	183.47K	186.05K
COGS % of Revenue	1.11%	0.89%	2.34%	2.1%	0.25%	0.05%	-	-	-	-
Gross Profit+	-81.56K	143.86K	-306.17K	-233.47K	309.58K	311.2K	-118.79K	-118.19K	-183.47K	-186.05K
Gross Margin %	-0.11%	0.11%	-1.34%	-1.1%	0.75%	0.95%	-	-	-	-
Gross Profit Growth %	0.79%	2.76%	-3.13%	0.24%	2.33%	0.01%	-1.38%	0.01%	-0.55%	-0.01%
Operating Expenses+	4.26M	5.05M	4.92M	4.84M	3.14M	6.71M	13.34M	17.59M	9.22M	7.01M
OpEx % of Revenue	5.61%	3.97%	21.54%	22.87%	7.65%	20.41%	-	-	-	-
Selling, General & Admin	3.23M	3.32M	2.94M	2.76M	2.05M	3.38M	5.73M	5.04M	4.24M	4.13M
SG&A % of Revenue	4.25%	2.61%	12.9%	13.02%	4.98%	10.29%	-	-	-	-
Research & Development	1.03M	1.73M	1.97M	2.09M	1.1M	3.33M	17.95M	13.34M	4.79M	2.88M
R&D % of Revenue	1.36%	1.36%	8.64%	9.85%	2.67%	10.13%	-	-	-	-
Other Operating Expenses	0	24.63K	0	0	0	37.41K	-10.34M	-780.26K	0	0
Operating Income+	-4.34M	-4.91M	-5.22M	-5.08M	-2.83M	-6.4M	-23.68M	-18.37M	-9.22M	-7.01M
Operating Margin %	-5.72%	-3.86%	-22.89%	-23.97%	-6.89%	-19.47%	-	-	-	-
Operating Income Growth %	0.24%	-0.13%	-0.06%	0.03%	0.44%	-1.26%	-2.7%	0.22%	0.5%	0.24%
EBITDA+	-4.18M	-4.76M	-5.05M	-4.89M	-2.83M	-6.34M	-23.56M	-18.25M	-9.04M	-6.83M
EBITDA Margin %	-5.51%	-3.74%	-22.1%	-23.08%	-6.88%	-19.29%	-	-	-	-
EBITDA Growth %	0.25%	-0.14%	-0.06%	0.03%	0.42%	-1.24%	-2.71%	0.23%	0.5%	0.24%
D&A (Non-Cash Add-back)	159.52K	149.56K	179.32K	188.37K	6.37K	57.56K	118.79K	118.19K	183.47K	186.05K
EBIT	-4.34M	-4.91M	-5.03M	-5.04M	-2.83M	-6.4M	-13.34M	-17.55M	-8.37M	-6.17M
Net Interest Income+	0	0	0	0	56.84K	37.78K	11.16K	64	289.85K	153.5K
Interest Income	0	0	0	0	56.84K	37.78K	11.16K	64	289.85K	153.5K
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	1.53M	-110.52K	194.7K	40.1K	-309.44K	37.41K	10.34M	822.67K	849.14K	845.5K
Pretax Income+	-2.81M	-5.02M	-5.03M	-5.04M	-2.78M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Pretax Margin %	-3.7%	-3.95%	-22.03%	-23.78%	-6.76%	-19.35%	-	-	-	-
Income Tax+	36.8K	7.2K	800	800	-55.4K	800	800	800	800	800
Effective Tax Rate %	1.01%	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-2.84M	-5.03M	-5.03M	-5.04M	-2.72M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Net Margin %	-3.75%	-3.95%	-22.04%	-23.79%	-6.62%	-19.36%	-	-	-	-
Net Income Growth %	0.66%	-0.77%	-0%	-0%	0.46%	-1.34%	-1.1%	-0.32%	0.52%	0.26%
Net Income (Continuing)	-2.84M	-5.03M	-5.03M	-5.04M	-3.14M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-15.01	-23.92	-211.28	-10.54	-4.15	-5.18	-7.73	-8.37	-2.93	-1.93
EPS Growth %	0.68%	-0.59%	-7.83%	0.95%	0.61%	-0.25%	-0.49%	-0.08%	0.65%	0.34%
EPS (Basic)	-15.01	-23.92	-218.72	-10.54	-4.15	-5.18	-7.74	-8.37	-2.93	-1.93
Diluted Shares Outstanding	189.45K	210.15K	23.81K	478.23K	655.32K	1.23M	1.73M	2.1M	2.86M	3.2M
Basic Shares Outstanding	189.45K	210.15K	23K	478.23K	655K	1.23M	1.73M	2.1M	2.86M	3.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	9.87M	12.1M	6.76M	10.66M	5.64M	8.1M	12.09M	9.09M	6.44M	1.68M
Cash & Short-Term Investments	8.97M	11.41M	6.57M	10.3M	5.03M	7.21M	7.84M	7.09M	5.36M	1.04M
Cash Only	3.96M	7.42M	4.57M	4.23M	5.03M	7.21M	7.84M	7.09M	5.36M	1.04M
Short-Term Investments	5.02M	3.99M	1.99M	6.08M	0	0	0	0	0	0
Accounts Receivable	157.6K	85.81K	1.29K	41.25K	217.1K	87.45K	3.3M	1.26M	626.54K	270.91K
Days Sales Outstanding	75.82	24.63	2.06	71.06	192.86	97.07	-	-	-	-
Inventory	557.28K	249.43K	68.11K	224.27K	-217.1K	0	0	0	0	0
Days Inventory Outstanding	242.08	80.72	46.52	183.82	-	-	-	-	-	-
Other Current Assets	0	0	0	86.92K	0	0	948.64K	0	448.91K	367.39K
Total Non-Current Assets+	519.31K	838.15K	961.56K	1.12M	73.06K	2.66M	2.49M	2.48M	2.45M	2.14M
Property, Plant & Equipment	503.41K	756.11K	879.52K	1.06M	73.06K	174.82K	111.56K	31.16K	100.08K	18.36K
Fixed Asset Turnover	1.51x	1.68x	0.26x	0.20x	5.62x	1.88x	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	2.48M	2.38M	2.28M	2.18M	2.08M
Long-Term Investments	0	66.69K	66.69K	46.46K	0	0	0	0	0	0
Other Non-Current Assets	15.9K	15.34K	15.34K	15.34K	0	0	0	171.46K	173.49K	41.15K
Total Assets+	10.39M	12.94M	7.72M	11.78M	5.72M	10.76M	14.58M	11.58M	8.89M	3.81M
Asset Turnover	0.07x	0.10x	0.03x	0.02x	0.07x	0.03x	-	-	-	-
Asset Growth %	-0.28%	0.25%	-0.4%	0.53%	-0.51%	0.88%	0.36%	-0.21%	-0.23%	-0.57%
Total Current Liabilities+	2.38M	623.64K	320.95K	493.38K	461.63K	1.53M	1.46M	2.14M	1.82M	1.83M
Accounts Payable	157.6K	623.64K	320.95K	493.38K	424.63K	1.46M	1.38M	2.12M	1.75M	1.81M
Days Payables Outstanding	68.46	201.83	219.19	404.4	1.53K	30.28K	4.24K	6.55K	3.48K	3.56K
Short-Term Debt	0	0	0	0	0	69.73K	0	18.98K	0	0
Deferred Revenue (Current)	173.33K	0	0	0	0	-1000K	-1000K	-1000K	0	0
Other Current Liabilities	1.55M	0	0	0	0	-69.73K	0	-18.98K	0	0
Current Ratio	4.14x	19.40x	21.06x	21.60x	12.23x	5.30x	8.29x	4.25x	3.53x	0.91x
Quick Ratio	3.91x	19.00x	20.85x	21.14x	12.70x	5.30x	8.29x	4.25x	3.53x	0.91x
Cash Conversion Cycle	249.44	-96.48	-170.61	-149.51	-	-	-	-	-	-
Total Non-Current Liabilities+	173.33K	0	0	0	0	2.6M	67.71K	43.66K	19.77K	126K
Long-Term Debt	0	0	0	0	0	94.46K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	94.46K	20.51K	0	19.77K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	126K
Other Non-Current Liabilities	0	0	0	0	0	2.41M	47.2K	43.66K	0	0
Total Liabilities	2.38M	623.64K	320.95K	493.38K	461.63K	4.13M	1.53M	2.18M	1.84M	1.83M
Total Debt+	0	0	0	0	0	164.19K	99.32K	18.98K	94.49K	19.87K
Net Debt	-3.96M	-7.42M	-4.57M	-4.23M	-5.03M	-7.05M	-7.74M	-7.07M	-5.27M	-1.02M
Debt / Equity	-	-	-	-	-	0.02x	0.01x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	8.01M	12.31M	7.4M	11.29M	5.26M	6.63M	13.06M	9.39M	7.05M	1.98M
Equity Growth %	0.04%	0.54%	-0.4%	0.53%	-0.53%	0.26%	0.97%	-0.28%	-0.25%	-0.72%
Book Value per Share	42.26	58.60	310.75	23.60	8.02	5.39	7.57	4.48	2.47	0.62
Total Shareholders' Equity	8.01M	12.31M	7.4M	11.29M	5.26M	6.63M	13.06M	9.39M	7.05M	1.98M
Common Stock	38.11M	47.28M	48.35M	56.65M	12.01M	18.5M	34.89M	42.47M	46.64M	47.24M
Retained Earnings	-35.34M	-40.36M	-45.39M	-50.43M	-6.73M	-13.13M	-26.5M	-44.04M	-52.42M	-58.59M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	5.39M	4.44M	5.06M	-342.07K	-287.2K	-205.26K	-213.6K	-214.65K	-242.61K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	-4.41M	-4.51M	-4.7M	-4.62M	-4.85M	-4.99M	-13.66M	-12.28M	-6.64M	-4.89M
Operating CF Margin %	-5.82%	-3.54%	-20.59%	-21.79%	-11.79%	-15.17%	-	-	-	-
Operating CF Growth %	-0.03%	-0.02%	-0.04%	0.02%	-0.05%	-0.03%	-1.74%	0.1%	0.46%	0.26%
Net Income	-2.84M	-5.03M	-5.03M	-5.04M	-2.78M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Depreciation & Amortization	159.52K	149.56K	179.32K	188.37K	4.78K	57.56K	118.79K	118.19K	183.47K	186.05K
Stock-Based Compensation	267.22K	259.38K	115.55K	154.31K	46.51K	598.36K	3.2M	2.26M	1.25M	537.49K
Deferred Taxes	0	0	0	55.3K	-2.76M	-655.92K	-3.31M	-2.38M	-308K	0
Other Non-Cash Items	-1.48M	135.16K	-162.03K	12.42K	2.75M	655.92K	3.31M	2.38M	308K	-14.77K
Working Capital Changes	-518.38K	-23.65K	198.16K	13.04K	-2.11M	721.97K	-3.64M	2.89M	308K	571.07K
Change in Receivables	-113.92K	71.83K	84.57K	-40K	9.74K	127.13K	-3.23M	2.03B	562.77K	356.34K
Change in Inventory	-522.39K	307.85K	181.32K	-156.15K	77.91K	0	0	0	0	0
Change in Payables	31.26K	-230.55K	-302.73K	172.45K	-1.88M	998.9K	-124.72K	882.84K	-556.27K	0
Cash from Investing+	122.47K	557.41K	1.69M	-4.47M	6.42M	19.07K	-6.15K	-5.66K	0	0
Capital Expenditures	-274.59K	-402.27K	-302.73K	-382.81K	-8.1K	-34.34K	-6.15K	-5.66K	3	0
CapEx % of Revenue	0.36%	0.32%	1.33%	1.81%	0.02%	0.1%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	12M	0	0	36.74K	23.93K	0	0	0	0
Cash from Financing+	106.78K	7.31M	5.91K	8.77M	0	7.09M	14.17M	11.63M	4.83M	592.03K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	5.91K	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.69M	-4.91M	-5M	-5M	-4.85M	-5.02M	-13.67M	-12.28M	-6.64M	-4.89M
FCF Margin %	-6.18%	-3.86%	-21.91%	-23.59%	-11.81%	-15.27%	-	-	-	-
FCF Growth %	-0.03%	-0.05%	-0.02%	0%	0.03%	-0.03%	-1.72%	0.1%	0.46%	0.26%
FCF per Share	-24.74	-23.35	-210.10	-10.45	-7.41	-4.08	-7.92	-5.86	-2.32	-1.53
FCF Conversion (FCF/Net Income)	1.55x	0.90x	0.93x	0.92x	1.78x	0.78x	1.02x	0.70x	0.79x	0.79x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	36.8K	7.2K	800	800	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.2%	-49.47%	-51.04%	-53.93%	-32.9%	-107.08%	-135.54%	-156.34%	-101.88%	-136.66%
Return on Invested Capital (ROIC)	-80.35%	-82.29%	-101.44%	-77.03%	-58.3%	-	-724.94%	-360.79%	-337.32%	-383.24%
Gross Margin	-10.75%	11.31%	-134.11%	-110.21%	75.35%	94.65%	-	-	-	-
Net Margin	-374.73%	-395.23%	-2203.65%	-2378.56%	-662.33%	-1935.59%	-	-	-	-
Debt / Equity	-	-	-	-	-	0.02x	0.01x	0.00x	0.01x	0.01x
FCF Conversion	1.55x	0.90x	0.93x	0.92x	1.78x	0.78x	1.02x	0.70x	0.79x	0.79x
Revenue Growth	103.88%	67.62%	-82.05%	-7.2%	93.94%	-19.97%	-100%	-	-	-

Revenue by Segment

	2018
Product	211.85K
Product Growth	-

Frequently Asked Questions

Growth & Financials

Edesa Biotech, Inc. (EDSA) grew revenue by 0.0% over the past year. Growth has been modest.

Edesa Biotech, Inc. (EDSA) reported a net loss of $5.9M for fiscal year 2024.

Dividend & Returns

Edesa Biotech, Inc. (EDSA) has a return on equity (ROE) of -136.7%. Negative ROE indicates the company is unprofitable.

Edesa Biotech, Inc. (EDSA) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Edesa Biotech, Inc. (EDSA) 10-Year Financial Performance & Capital Metrics

EDSA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $0
EBITDA -$7M +24.5%
Net Income -$6M +26.3%
EPS (Diluted) -1.93 +34.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -136.66% -34.1%
ROIC -383.24% -13.6%
Debt/Equity 0.01 -25.2%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 11 (bottom 11%)
✗Shares diluted 11.8% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM100%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM14.57%

EPS CAGR

10Y-

5Y-

3Y-

TTM39.82%

ROCE

10Y Avg-96.1%

5Y Avg-145.97%

3Y Avg-143.22%

Latest-155.03%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	758.69K	1.27M	228.29K	211.85K	410.87K	328.8K	0	0	0	0
Revenue Growth %	1.04%	0.68%	-0.82%	-0.07%	0.94%	-0.2%	-1%	-	-	-
Cost of Goods Sold+	840.25K	1.13M	534.45K	445.32K	101.29K	17.6K	118.79K	118.19K	183.47K	186.05K
COGS % of Revenue	1.11%	0.89%	2.34%	2.1%	0.25%	0.05%	-	-	-	-
Gross Profit+	-81.56K	143.86K	-306.17K	-233.47K	309.58K	311.2K	-118.79K	-118.19K	-183.47K	-186.05K
Gross Margin %	-0.11%	0.11%	-1.34%	-1.1%	0.75%	0.95%	-	-	-	-
Gross Profit Growth %	0.79%	2.76%	-3.13%	0.24%	2.33%	0.01%	-1.38%	0.01%	-0.55%	-0.01%
Operating Expenses+	4.26M	5.05M	4.92M	4.84M	3.14M	6.71M	13.34M	17.59M	9.22M	7.01M
OpEx % of Revenue	5.61%	3.97%	21.54%	22.87%	7.65%	20.41%	-	-	-	-
Selling, General & Admin	3.23M	3.32M	2.94M	2.76M	2.05M	3.38M	5.73M	5.04M	4.24M	4.13M
SG&A % of Revenue	4.25%	2.61%	12.9%	13.02%	4.98%	10.29%	-	-	-	-
Research & Development	1.03M	1.73M	1.97M	2.09M	1.1M	3.33M	17.95M	13.34M	4.79M	2.88M
R&D % of Revenue	1.36%	1.36%	8.64%	9.85%	2.67%	10.13%	-	-	-	-
Other Operating Expenses	0	24.63K	0	0	0	37.41K	-10.34M	-780.26K	0	0
Operating Income+	-4.34M	-4.91M	-5.22M	-5.08M	-2.83M	-6.4M	-23.68M	-18.37M	-9.22M	-7.01M
Operating Margin %	-5.72%	-3.86%	-22.89%	-23.97%	-6.89%	-19.47%	-	-	-	-
Operating Income Growth %	0.24%	-0.13%	-0.06%	0.03%	0.44%	-1.26%	-2.7%	0.22%	0.5%	0.24%
EBITDA+	-4.18M	-4.76M	-5.05M	-4.89M	-2.83M	-6.34M	-23.56M	-18.25M	-9.04M	-6.83M
EBITDA Margin %	-5.51%	-3.74%	-22.1%	-23.08%	-6.88%	-19.29%	-	-	-	-
EBITDA Growth %	0.25%	-0.14%	-0.06%	0.03%	0.42%	-1.24%	-2.71%	0.23%	0.5%	0.24%
D&A (Non-Cash Add-back)	159.52K	149.56K	179.32K	188.37K	6.37K	57.56K	118.79K	118.19K	183.47K	186.05K
EBIT	-4.34M	-4.91M	-5.03M	-5.04M	-2.83M	-6.4M	-13.34M	-17.55M	-8.37M	-6.17M
Net Interest Income+	0	0	0	0	56.84K	37.78K	11.16K	64	289.85K	153.5K
Interest Income	0	0	0	0	56.84K	37.78K	11.16K	64	289.85K	153.5K
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	1.53M	-110.52K	194.7K	40.1K	-309.44K	37.41K	10.34M	822.67K	849.14K	845.5K
Pretax Income+	-2.81M	-5.02M	-5.03M	-5.04M	-2.78M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Pretax Margin %	-3.7%	-3.95%	-22.03%	-23.78%	-6.76%	-19.35%	-	-	-	-
Income Tax+	36.8K	7.2K	800	800	-55.4K	800	800	800	800	800
Effective Tax Rate %	1.01%	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-2.84M	-5.03M	-5.03M	-5.04M	-2.72M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Net Margin %	-3.75%	-3.95%	-22.04%	-23.79%	-6.62%	-19.36%	-	-	-	-
Net Income Growth %	0.66%	-0.77%	-0%	-0%	0.46%	-1.34%	-1.1%	-0.32%	0.52%	0.26%
Net Income (Continuing)	-2.84M	-5.03M	-5.03M	-5.04M	-3.14M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-15.01	-23.92	-211.28	-10.54	-4.15	-5.18	-7.73	-8.37	-2.93	-1.93
EPS Growth %	0.68%	-0.59%	-7.83%	0.95%	0.61%	-0.25%	-0.49%	-0.08%	0.65%	0.34%
EPS (Basic)	-15.01	-23.92	-218.72	-10.54	-4.15	-5.18	-7.74	-8.37	-2.93	-1.93
Diluted Shares Outstanding	189.45K	210.15K	23.81K	478.23K	655.32K	1.23M	1.73M	2.1M	2.86M	3.2M
Basic Shares Outstanding	189.45K	210.15K	23K	478.23K	655K	1.23M	1.73M	2.1M	2.86M	3.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	9.87M	12.1M	6.76M	10.66M	5.64M	8.1M	12.09M	9.09M	6.44M	1.68M
Cash & Short-Term Investments	8.97M	11.41M	6.57M	10.3M	5.03M	7.21M	7.84M	7.09M	5.36M	1.04M
Cash Only	3.96M	7.42M	4.57M	4.23M	5.03M	7.21M	7.84M	7.09M	5.36M	1.04M
Short-Term Investments	5.02M	3.99M	1.99M	6.08M	0	0	0	0	0	0
Accounts Receivable	157.6K	85.81K	1.29K	41.25K	217.1K	87.45K	3.3M	1.26M	626.54K	270.91K
Days Sales Outstanding	75.82	24.63	2.06	71.06	192.86	97.07	-	-	-	-
Inventory	557.28K	249.43K	68.11K	224.27K	-217.1K	0	0	0	0	0
Days Inventory Outstanding	242.08	80.72	46.52	183.82	-	-	-	-	-	-
Other Current Assets	0	0	0	86.92K	0	0	948.64K	0	448.91K	367.39K
Total Non-Current Assets+	519.31K	838.15K	961.56K	1.12M	73.06K	2.66M	2.49M	2.48M	2.45M	2.14M
Property, Plant & Equipment	503.41K	756.11K	879.52K	1.06M	73.06K	174.82K	111.56K	31.16K	100.08K	18.36K
Fixed Asset Turnover	1.51x	1.68x	0.26x	0.20x	5.62x	1.88x	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	2.48M	2.38M	2.28M	2.18M	2.08M
Long-Term Investments	0	66.69K	66.69K	46.46K	0	0	0	0	0	0
Other Non-Current Assets	15.9K	15.34K	15.34K	15.34K	0	0	0	171.46K	173.49K	41.15K
Total Assets+	10.39M	12.94M	7.72M	11.78M	5.72M	10.76M	14.58M	11.58M	8.89M	3.81M
Asset Turnover	0.07x	0.10x	0.03x	0.02x	0.07x	0.03x	-	-	-	-
Asset Growth %	-0.28%	0.25%	-0.4%	0.53%	-0.51%	0.88%	0.36%	-0.21%	-0.23%	-0.57%
Total Current Liabilities+	2.38M	623.64K	320.95K	493.38K	461.63K	1.53M	1.46M	2.14M	1.82M	1.83M
Accounts Payable	157.6K	623.64K	320.95K	493.38K	424.63K	1.46M	1.38M	2.12M	1.75M	1.81M
Days Payables Outstanding	68.46	201.83	219.19	404.4	1.53K	30.28K	4.24K	6.55K	3.48K	3.56K
Short-Term Debt	0	0	0	0	0	69.73K	0	18.98K	0	0
Deferred Revenue (Current)	173.33K	0	0	0	0	-1000K	-1000K	-1000K	0	0
Other Current Liabilities	1.55M	0	0	0	0	-69.73K	0	-18.98K	0	0
Current Ratio	4.14x	19.40x	21.06x	21.60x	12.23x	5.30x	8.29x	4.25x	3.53x	0.91x
Quick Ratio	3.91x	19.00x	20.85x	21.14x	12.70x	5.30x	8.29x	4.25x	3.53x	0.91x
Cash Conversion Cycle	249.44	-96.48	-170.61	-149.51	-	-	-	-	-	-
Total Non-Current Liabilities+	173.33K	0	0	0	0	2.6M	67.71K	43.66K	19.77K	126K
Long-Term Debt	0	0	0	0	0	94.46K	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	94.46K	20.51K	0	19.77K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	126K
Other Non-Current Liabilities	0	0	0	0	0	2.41M	47.2K	43.66K	0	0
Total Liabilities	2.38M	623.64K	320.95K	493.38K	461.63K	4.13M	1.53M	2.18M	1.84M	1.83M
Total Debt+	0	0	0	0	0	164.19K	99.32K	18.98K	94.49K	19.87K
Net Debt	-3.96M	-7.42M	-4.57M	-4.23M	-5.03M	-7.05M	-7.74M	-7.07M	-5.27M	-1.02M
Debt / Equity	-	-	-	-	-	0.02x	0.01x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	8.01M	12.31M	7.4M	11.29M	5.26M	6.63M	13.06M	9.39M	7.05M	1.98M
Equity Growth %	0.04%	0.54%	-0.4%	0.53%	-0.53%	0.26%	0.97%	-0.28%	-0.25%	-0.72%
Book Value per Share	42.26	58.60	310.75	23.60	8.02	5.39	7.57	4.48	2.47	0.62
Total Shareholders' Equity	8.01M	12.31M	7.4M	11.29M	5.26M	6.63M	13.06M	9.39M	7.05M	1.98M
Common Stock	38.11M	47.28M	48.35M	56.65M	12.01M	18.5M	34.89M	42.47M	46.64M	47.24M
Retained Earnings	-35.34M	-40.36M	-45.39M	-50.43M	-6.73M	-13.13M	-26.5M	-44.04M	-52.42M	-58.59M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	5.39M	4.44M	5.06M	-342.07K	-287.2K	-205.26K	-213.6K	-214.65K	-242.61K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	-4.41M	-4.51M	-4.7M	-4.62M	-4.85M	-4.99M	-13.66M	-12.28M	-6.64M	-4.89M
Operating CF Margin %	-5.82%	-3.54%	-20.59%	-21.79%	-11.79%	-15.17%	-	-	-	-
Operating CF Growth %	-0.03%	-0.02%	-0.04%	0.02%	-0.05%	-0.03%	-1.74%	0.1%	0.46%	0.26%
Net Income	-2.84M	-5.03M	-5.03M	-5.04M	-2.78M	-6.36M	-13.34M	-17.55M	-8.37M	-6.17M
Depreciation & Amortization	159.52K	149.56K	179.32K	188.37K	4.78K	57.56K	118.79K	118.19K	183.47K	186.05K
Stock-Based Compensation	267.22K	259.38K	115.55K	154.31K	46.51K	598.36K	3.2M	2.26M	1.25M	537.49K
Deferred Taxes	0	0	0	55.3K	-2.76M	-655.92K	-3.31M	-2.38M	-308K	0
Other Non-Cash Items	-1.48M	135.16K	-162.03K	12.42K	2.75M	655.92K	3.31M	2.38M	308K	-14.77K
Working Capital Changes	-518.38K	-23.65K	198.16K	13.04K	-2.11M	721.97K	-3.64M	2.89M	308K	571.07K
Change in Receivables	-113.92K	71.83K	84.57K	-40K	9.74K	127.13K	-3.23M	2.03B	562.77K	356.34K
Change in Inventory	-522.39K	307.85K	181.32K	-156.15K	77.91K	0	0	0	0	0
Change in Payables	31.26K	-230.55K	-302.73K	172.45K	-1.88M	998.9K	-124.72K	882.84K	-556.27K	0
Cash from Investing+	122.47K	557.41K	1.69M	-4.47M	6.42M	19.07K	-6.15K	-5.66K	0	0
Capital Expenditures	-274.59K	-402.27K	-302.73K	-382.81K	-8.1K	-34.34K	-6.15K	-5.66K	3	0
CapEx % of Revenue	0.36%	0.32%	1.33%	1.81%	0.02%	0.1%	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	12M	0	0	36.74K	23.93K	0	0	0	0
Cash from Financing+	106.78K	7.31M	5.91K	8.77M	0	7.09M	14.17M	11.63M	4.83M	592.03K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	5.91K	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.69M	-4.91M	-5M	-5M	-4.85M	-5.02M	-13.67M	-12.28M	-6.64M	-4.89M
FCF Margin %	-6.18%	-3.86%	-21.91%	-23.59%	-11.81%	-15.27%	-	-	-	-
FCF Growth %	-0.03%	-0.05%	-0.02%	0%	0.03%	-0.03%	-1.72%	0.1%	0.46%	0.26%
FCF per Share	-24.74	-23.35	-210.10	-10.45	-7.41	-4.08	-7.92	-5.86	-2.32	-1.53
FCF Conversion (FCF/Net Income)	1.55x	0.90x	0.93x	0.92x	1.78x	0.78x	1.02x	0.70x	0.79x	0.79x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	36.8K	7.2K	800	800	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-36.2%	-49.47%	-51.04%	-53.93%	-32.9%	-107.08%	-135.54%	-156.34%	-101.88%	-136.66%
Return on Invested Capital (ROIC)	-80.35%	-82.29%	-101.44%	-77.03%	-58.3%	-	-724.94%	-360.79%	-337.32%	-383.24%
Gross Margin	-10.75%	11.31%	-134.11%	-110.21%	75.35%	94.65%	-	-	-	-
Net Margin	-374.73%	-395.23%	-2203.65%	-2378.56%	-662.33%	-1935.59%	-	-	-	-
Debt / Equity	-	-	-	-	-	0.02x	0.01x	0.00x	0.01x	0.01x
FCF Conversion	1.55x	0.90x	0.93x	0.92x	1.78x	0.78x	1.02x	0.70x	0.79x	0.79x
Revenue Growth	103.88%	67.62%	-82.05%	-7.2%	93.94%	-19.97%	-100%	-	-	-

Revenue by Segment

	2018
Product	211.85K
Product Growth	-

Frequently Asked Questions

Growth & Financials

Edesa Biotech, Inc. (EDSA) grew revenue by 0.0% over the past year. Growth has been modest.

Edesa Biotech, Inc. (EDSA) reported a net loss of $5.9M for fiscal year 2024.

Dividend & Returns

Edesa Biotech, Inc. (EDSA) has a return on equity (ROE) of -136.7%. Negative ROE indicates the company is unprofitable.

Edesa Biotech, Inc. (EDSA) had negative free cash flow of $6.6M in fiscal year 2024, likely due to heavy capital investments.